The Platform
Eight stages. One integrated oncology development platform.
A vertically integrated approach connecting laboratory discovery to industrial manufacture — engineered for regulatory scrutiny and global scale.
Interactive process flow
From molecule to marketable medicine.
Research
Target selection, literature landscape and molecule characterisation.
Formulation
Dosage form design — parenterals, injectables, complex solid orals.
Development
QbD & DOE-driven formulation and process development.
Optimisation
Media, cell line, process parameter and analytical optimisation.
Scale-up
Bench to pilot to clinical to commercial scale bioreactors.
Manufacturing
cGMP-ready manufacturing with disciplined change control.
Quality
Analytical method validation and full release specifications.
Commercialisation
Regulatory dossiers, technology transfer, launch readiness.
Modalities
Built for small molecules and biologics alike.
Our platform is engineered to handle the full spectrum of oncology therapeutics — from sterile injectable small molecules to complex monoclonal antibody biosimilars developed with our technical partner, The Antibody Company (TAC).
Small molecule anti-cancer agents
Sterile parenteral and complex oral dosage forms with rigorous stability programmes.
Monoclonal antibody biosimilars
Cell line development, upstream / downstream process design, formulation and characterisation.
Combination products
Cytotoxic-antibody conjugates and combination regimens engineered for clinical performance.
Advanced delivery systems
Hot melt extrusion, spray drying, osmotic delivery and modified-release technology transfer.